Is Intuitive Surgical (ISRG) overvalued or fairly valued?

MarketChacha shows Intuitive Surgical's valuation in context — a trailing P/E of about 47.2, a forward P/E of about 32.6, a price-to-book of about 7.7 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

Does Intuitive Surgical's reported profit turn into cash?

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash. MarketChacha computes this cash-conversion check (1.04×) from reported figures — education, not a rating.

What is Intuitive Surgical's revenue?

Intuitive Surgical reported revenue of $10.1B for FY2025, with net profit of $2.9B, per official filings.

What is the share price of Intuitive Surgical (ISRG)?

Intuitive Surgical last traded at $393.38 (+3.8% on the day), as of 8/10/2026 — a delayed quote shown for education, not investment advice.

Intuitive Surgical

ISRG · NASDAQ · Healthcare · United States

Snapshot

TickerISRG

ExchangeNASDAQ

SectorHealthcare

IndustryMedical Instruments & Supplies

CountryUnited States

Employees17,021

HeadquartersSunnyvale, United States

Websitewww.intuitive.com

Filings tracked14

About Intuitive Surgical

Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. It offers the da Vinci Surgical System that enables surgical procedures using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic endoluminal procedures enabling minimally invasive biopsies in the lung. The company also provides a suite of stapling, energy, and core instrumentation for its multi-port da Vinci surgical systems; progressive learning pathways to support the use of its technology; infrastructure of customer service and support specialists, a complement of services to its customers, including installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring; and integrated digital capabilities providing connected offerings, streamlining performance for hospitals with program-enhancing insights. It sells its products through direct sales organizations, such as capital and clinical sales teams. Intuitive Surgical, Inc. was incorporated in 1995 and is headquartered in Sunnyvale, California.

Who owns it

Insiders0.5%
Institutions89.3%
Public & other10.1%

3,139 institutional holders

Ownership breakdown from public market data.

Top holders

Blackrock Inc.8.50%
Vanguard Capital Management LLC6.53%
State Street Corporation4.55%
Price (T.Rowe) Associates Inc3.54%
Invesco Ltd.3.17%
Geode Capital Management, LLC2.40%
Capital World Investors2.28%
Vanguard Portfolio Management LLC2.05%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

No major accounting red flags in the fundamentals we have — profit is backed by cash and returns look healthy.

Cash conversion1.04×

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash.

Net margin trend25.2% → 28.4%

Margin has expanded by about 3.1 points — the business is getting more profitable.

Return on equity16.0%

Latest ROE of 16.0% — capital is generating a healthy return.

Growth qualityrev 19% · PAT 26%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $3.2B · EPS 2.84

Est. earnings growth +12.4%

Next fiscal year

Rev $13.2B · EPS 12.07

Est. earnings growth +11.8%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2025)

$10.1B

Net margin

28.4%

ROE

16.0%

Revenue CAGR (2y)

+18.9%

Profit CAGR (2y)

+26.0%

EPS (FY2025)

7.87

Net profit (FY2025)

$2.9B

Ask MarketChacha about ISRG

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$10.1B	$2.9B	7.87	28.4%	16.0%
FY2024	$8.4B	$2.3B	6.42	27.8%	14.1%
FY2023	$7.1B	$1.8B	5.03	25.2%	13.5%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q2	$2.9B	$818.1M	2.29	28.3%
2026Q1	$2.8B	$821.5M	2.28	29.6%
2025Q3	$2.5B	$704.4M	1.95	28.1%
2025Q2	$2.4B	$658.4M	1.81	27.0%
2025Q1	$2.3B	$698.4M	1.92	31.0%
2024Q3	$2.0B	$565.1M	1.56	27.7%
2024Q2	$2.0B	$526.9M	1.46	26.2%
2024Q1	$1.9B	$544.9M	1.51	28.8%
2023Q3	$1.7B	$415.7M	1.16	23.8%
2023Q2	$1.8B	$420.8M	1.18	24.0%
2023Q1	$1.7B	$355.3M	1.00	20.9%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

8-K — Bylaw/charter change, Exhibits
SEC7/27/2026material
10-Q filing
SEC7/21/2026
8-K — Results of operations, Exhibits
SEC7/16/2026material
8-K — Executive/director change, Exhibits
SEC5/28/2026material
8-K — Executive/director change, Shareholder vote results, Reg FD disclosure
SEC5/4/2026material
10-Q filing
SEC4/22/2026
8-K — Results of operations, Exhibits
SEC4/21/2026material
8-K — Other events, Exhibits
SEC3/2/2026material
10-K filing
SEC2/3/2026
8-K — Results of operations, Exhibits
SEC1/22/2026material
8-K — Results of operations, Exhibits
SEC1/14/2026material

2025

8-K — Executive/director change
SEC12/18/2025material
10-Q filing
SEC10/22/2025
8-K — Results of operations, Exhibits
SEC10/21/2025material

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.